348 related articles for article (PubMed ID: 29764444)
21. Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Duval R; Bui LC; Mathieu C; Nian Q; Berthelet J; Xu X; Haddad I; Vinh J; Dupret JM; Busi F; Guidez F; Chomienne C; Rodrigues-Lima F
J Biol Chem; 2019 Aug; 294(33):12483-12494. PubMed ID: 31248982
[TBL] [Abstract][Full Text] [Related]
22. PTPN2 induced by inflammatory response and oxidative stress contributed to glioma progression.
Wu L; Wang F; Xu J; Chen Z
J Cell Biochem; 2019 Nov; 120(11):19044-19051. PubMed ID: 31241223
[TBL] [Abstract][Full Text] [Related]
23. PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H
Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065
[TBL] [Abstract][Full Text] [Related]
24. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Guan X; Luo L; Begum G; Kohanbash G; Song Q; Rao A; Amankulor N; Sun B; Sun D; Jia W
J Exp Clin Cancer Res; 2018 Oct; 37(1):255. PubMed ID: 30333031
[TBL] [Abstract][Full Text] [Related]
25. Redox Regulator
Chang Y; Li G; Zhai Y; Huang L; Feng Y; Wang D; Zhang W; Hu H
Front Immunol; 2020; 11():580934. PubMed ID: 33329553
[TBL] [Abstract][Full Text] [Related]
26. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
28. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
29. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
30. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
31. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
32. Mutant IDH1 regulates the tumor-associated immune system in gliomas.
Amankulor NM; Kim Y; Arora S; Kargl J; Szulzewsky F; Hanke M; Margineantu DH; Rao A; Bolouri H; Delrow J; Hockenbery D; Houghton AM; Holland EC
Genes Dev; 2017 Apr; 31(8):774-786. PubMed ID: 28465358
[TBL] [Abstract][Full Text] [Related]
33. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
Front Immunol; 2019; 10():1756. PubMed ID: 31428092
[No Abstract] [Full Text] [Related]
34. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.
Wang X; Yang Q; Liu N; Bian Q; Gao M; Hou X
Pathol Oncol Res; 2021; 27():1609825. PubMed ID: 34629960
[No Abstract] [Full Text] [Related]
35. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
36. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
37. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.
Wang ZL; Zhang CB; Liu YQ; Wang Z; Jiang T
CNS Neurosci Ther; 2019 Aug; 25(8):876-883. PubMed ID: 30912613
[TBL] [Abstract][Full Text] [Related]
39. Galectin-9: A Predictive Biomarker Negatively Regulating Immune Response in Glioma Patients.
Liang T; Wang X; Wang F; Feng E; You G
World Neurosurg; 2019 Dec; 132():e455-e462. PubMed ID: 31470166
[TBL] [Abstract][Full Text] [Related]
40. CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance.
Ma K; Chen S; Chen X; Zhao X; Yang J
J Mol Neurosci; 2022 Oct; 72(10):2106-2124. PubMed ID: 36006582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
